Esophagogastric Cancer Clinical Trial
Official title:
A Phase II Study of Nivolumab in Combination With FOLFOX and Regorafenib in Patients With HER2-Negative Metastatic Esophagogastric Cancer
The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer. Nivolumab is an antibody, like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD-1 (programmed cell death receptor-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them. FOLFOX is a combination of three standard chemotherapy drugs (leucovorin, 5-fluorouracil, and oxaliplatin) commonly used to treat your type of cancer. The drugs work by damaging the DNA in cancer cells, which can cause the cells to stop growing and die. Regorafenib is a type of drug called a tyrosine kinase inhibitor (TKI). This drug targets the tyrosine kinase protein found in or on the surface of cancer cells that the cells need to survive and grow. Blocking this protein may stop cancer cells from growing, or cause them to grow more slowly or to shrink. The study researchers think that combining nivolumab, FOLFOX, and regorafenib may be a more effective treatment for HER2-negative metastatic esophagogastric cancer than the usual chemotherapy treatment(s) alone.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05612048 -
A Study of Tooth Erosion in People With Esophagogastric Cancer
|
N/A | |
| Completed |
NCT04161781 -
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
||
| Completed |
NCT01803282 -
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05796102 -
PET-MRI Esophagus Feasibility Study
|
N/A | |
| Recruiting |
NCT04656041 -
Folfox+Irinotecan+Chemort In Esophageal Cancer
|
Phase 2 | |
| Withdrawn |
NCT02296671 -
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
|
Phase 2 | |
| Completed |
NCT02023996 -
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
|
N/A | |
| Recruiting |
NCT05117931 -
A Study of Amivantamab in People With Esophagogastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
| Completed |
NCT01167114 -
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03133650 -
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
|
Phase 1 |